secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-002888
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Allogene to start pivotal ALPHA3 trial in 1L LBCL; cuts 22% staff, partners with Foresight
--------------------------------------------------------------------------------

- Workforce reduction of ~22% with estimated $5.0M-$5.5M in severance charges, mostly in Q1 2024.
- Strategic collaboration with Foresight Diagnostics to develop MRD assay; Allogene to fund ~$26M.
- Plans to initiate pivotal Phase 2 ALPHA3 trial mid-2024 for cema-cel in 1L LBCL, targeting MRD+ patients (n~230).
- Deprioritizing 3L trials ALPHA2 and EXPAND; expects CD19 CAR T 2L/3L market to diminish.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/d103673d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer